This website uses cookies. It uses cookies to ensure that it gives you the best experience on our website. If you continue without agreeing to the cookie conditions, we'll assume that you are happy to receive all cookies on this website.
Read more >
More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Anticipated to Commence